company background image
COLL

Collegium Pharmaceutical NasdaqGS:COLL Stock Report

Last Price

US$22.50

Market Cap

US$755.4m

7D

-1.7%

1Y

25.1%

Updated

08 Dec, 2022

Data

Company Financials +
COLL fundamental analysis
Snowflake Score
Valuation6/6
Future Growth3/6
Past Performance0/6
Financial Health2/6
Dividends0/6

COLL Stock Overview

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management.

Collegium Pharmaceutical, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Collegium Pharmaceutical
Historical stock prices
Current Share PriceUS$22.50
52 Week HighUS$23.27
52 Week LowUS$14.04
Beta0.85
1 Month Change14.10%
3 Month Change29.76%
1 Year Change25.14%
3 Year Change8.64%
5 Year Change30.06%
Change since IPO83.08%

Recent News & Updates

Is Collegium Pharmaceutical (NASDAQ:COLL) Using Too Much Debt?

Oct 18
Is Collegium Pharmaceutical (NASDAQ:COLL) Using Too Much Debt?

Recent updates

Is Collegium Pharmaceutical (NASDAQ:COLL) Using Too Much Debt?

Oct 18
Is Collegium Pharmaceutical (NASDAQ:COLL) Using Too Much Debt?

Collegium Pharmaceutical (NASDAQ:COLL) Has A Somewhat Strained Balance Sheet

Jun 24
Collegium Pharmaceutical (NASDAQ:COLL) Has A Somewhat Strained Balance Sheet

There Is A Reason Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) Price Is Undemanding

Feb 15
There Is A Reason Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) Price Is Undemanding

We Think Collegium Pharmaceutical (NASDAQ:COLL) Can Stay On Top Of Its Debt

Oct 30
We Think Collegium Pharmaceutical (NASDAQ:COLL) Can Stay On Top Of Its Debt

Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) CEO Compensation Is Looking A Bit Stretched At The Moment

May 14
Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) CEO Compensation Is Looking A Bit Stretched At The Moment

Shareholders Will Be Pleased With The Quality of Collegium Pharmaceutical's (NASDAQ:COLL) Earnings

May 13
Shareholders Will Be Pleased With The Quality of Collegium Pharmaceutical's (NASDAQ:COLL) Earnings

We Think Collegium Pharmaceutical (NASDAQ:COLL) Is Taking Some Risk With Its Debt

May 01
We Think Collegium Pharmaceutical (NASDAQ:COLL) Is Taking Some Risk With Its Debt

Read This Before Judging Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) ROE

Feb 20
Read This Before Judging Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) ROE

Collegium Pharmaceutical (NASDAQ:COLL) Has A Somewhat Strained Balance Sheet

Jan 16
Collegium Pharmaceutical (NASDAQ:COLL) Has A Somewhat Strained Balance Sheet

Collegium Pharmaceutical (NASDAQ:COLL) Share Prices Have Dropped 27% In The Last Five Years

Dec 12
Collegium Pharmaceutical (NASDAQ:COLL) Share Prices Have Dropped 27% In The Last Five Years

Shareholder Returns

COLLUS PharmaceuticalsUS Market
7D-1.7%-0.3%-2.8%
1Y25.1%14.1%-19.6%

Return vs Industry: COLL exceeded the US Pharmaceuticals industry which returned 13.4% over the past year.

Return vs Market: COLL exceeded the US Market which returned -21.2% over the past year.

Price Volatility

Is COLL's price volatile compared to industry and market?
COLL volatility
COLL Average Weekly Movement6.4%
Pharmaceuticals Industry Average Movement11.0%
Market Average Movement7.4%
10% most volatile stocks in US Market15.5%
10% least volatile stocks in US Market3.3%

Stable Share Price: COLL is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 6% a week.

Volatility Over Time: COLL's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2002152Joe Ciaffonihttps://www.collegiumpharma.com

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ER for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003.

Collegium Pharmaceutical, Inc. Fundamentals Summary

How do Collegium Pharmaceutical's earnings and revenue compare to its market cap?
COLL fundamental statistics
Market CapUS$755.37m
Earnings (TTM)-US$42.84m
Revenue (TTM)US$361.68m

2.1x

P/S Ratio

-17.6x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
COLL income statement (TTM)
RevenueUS$361.68m
Cost of RevenueUS$68.78m
Gross ProfitUS$292.90m
Other ExpensesUS$335.73m
Earnings-US$42.84m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-1.28
Gross Margin80.98%
Net Profit Margin-11.84%
Debt/Equity Ratio366.9%

How did COLL perform over the long term?

See historical performance and comparison